The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab).

NEW YORK — Digital pathology firm Gestalt Diagnostics said on Monday that it has raised $7.5 million through a Series A financing round. The round was led by Cowles Ventures, TVF Funds, Inland Imaging ...

The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.

The first $25 million tranche was funded at close and used to retire Exagen's existing term debt facility with Innovatus Capital Partners.

Last week, readers were most interested in a story about Akoya's collaboration to identify markers predictive of response to checkpoint inhibitor therapy.

The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of ...

In one case a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other a firm paid and received kickbacks for unnecessary genetic testing.

The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease ...

SSID Group said that the assets acquired in the deal will complement its gastric health portfolio and let it offer a broader range of tests to US labs.

The project will use Akoya's PhenoCode Discovery IO60 Panel to look at matched pairs of immuno-oncology exceptional responders and hyper-progressors.

NEW YORK – Roche announced on Wednesday that it has received CE marking for its Chest Pain Triage algorithm to help rule in and rule out heart attacks in the emergency department.

The company has completed its FDA submission for the system and inked a deal with UAE-based healthcare provider Burjeel Holdings to deploy the system in its facilities.